New hope for Tough-to-Treat blood cancer: experimental therapy targets advanced myeloma
NCT ID NCT07376720
Summary
This study is testing a new type of personalized immune cell therapy called BCMA-GPRC5D CAR-T for people with advanced multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if this therapy is safe and can help patients live longer. Researchers will enroll about 28 participants to get an early look at how well this new approach might work.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 448000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.